BRAF and melanoma: The cytotoxicity of complexes 2 was evaluated in vitro by determining the half inhibitory concentrations (IC50) against four human cell lines: wild-type BRAF melanoma (MeWo), lung adenocarcinoma (A549), bladder cancer (T24), and non-cancerous skin keratinocytes (HaCaT).